178 related articles for article (PubMed ID: 30423409)
1. Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016.
Heimann SM; Vehreschild MJGT; Cornely OA; Heinz WJ; Grüner B; Silling G; Kessel J; Seidel D; Vehreschild JJ
J Hosp Infect; 2019 Mar; 101(3):339-346. PubMed ID: 30423409
[TBL] [Abstract][Full Text] [Related]
2. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.
Bagshaw E; Kuessner D; Posthumus J; Escrig C; Blackney M; Heimann SM; Cornely OA
Future Microbiol; 2017 May; 12():515-525. PubMed ID: 28191796
[TBL] [Abstract][Full Text] [Related]
3. Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals.
Heimann SM; Penack O; Heinz WJ; Rachow T; Egerer G; Kessel J; Claßen AY; Vehreschild JJ
Int J Infect Dis; 2019 Jun; 83():130-138. PubMed ID: 30978465
[TBL] [Abstract][Full Text] [Related]
4. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn).
Salmanton-García J; Seidel D; Koehler P; Mellinghoff SC; Herbrecht R; Klimko N; Ráčil Z; Falces-Romero I; Ingram P; Benítez-Peñuela MÁ; Rodríguez JY; Desoubeaux G; Barać A; García-Vidal C; Hoenigl M; Mehta SR; Cheng MP; Klyasova G; Heinz WJ; Iqbal N; Krause R; Ostermann H; Penack O; Schalk E; Sheppard DC; Willinger B; Wisplinghoff H; Vehreschild JJ; Cornely OA; Vehreschild MJGT;
J Antimicrob Chemother; 2019 Nov; 74(11):3315-3327. PubMed ID: 31393591
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study.
Kontoyiannis DP; Yang H; Song J; Kelkar SS; Yang X; Azie N; Harrington R; Fan A; Lee E; Spalding JR
BMC Infect Dis; 2016 Dec; 16(1):730. PubMed ID: 27905900
[TBL] [Abstract][Full Text] [Related]
6. Invasive mucormycosis in children with cancer: A retrospective study from the Infection Working Group of Italian Pediatric Hematology Oncology Association.
Muggeo P; Calore E; Decembrino N; Frenos S; De Leonardis F; Colombini A; Petruzziello F; Perruccio K; Berger M; Burnelli R; Zanazzo GA; Santoro N; Cesaro S
Mycoses; 2019 Feb; 62(2):165-170. PubMed ID: 30338581
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the prescription, consumption and costs of antifungal drugs in a pediatric hospital in Chile].
Barraza M; Barnafi N; Ortiz G; Torres JP; Coria P; Catalán P; Palma J; Morales J
Rev Chilena Infectol; 2018 Aug; 35(4):351-357. PubMed ID: 30534920
[TBL] [Abstract][Full Text] [Related]
9. [Mucormycosis: retrospective evaluation of 12 cases].
Arda B; Erdem A; Sipahi OR; Işıkgöz Taşbakan M; Pullukçu H; Taşbakan MS; Ceylan N; Metin DY; Midilli R; Yamazhan T; Ulusoy S
Mikrobiyol Bul; 2011 Jul; 45(3):504-11. PubMed ID: 21935783
[TBL] [Abstract][Full Text] [Related]
10. Monetary costs and hospital burden associated with the management of invasive fungal infections in Mexico: a multicenter study.
Corzo-León DE; Perales-Martínez D; Martin-Onraet A; Rivera-Martínez N; Camacho-Ortiz A; Villanueva-Lozano H
Braz J Infect Dis; 2018; 22(5):360-370. PubMed ID: 30395800
[TBL] [Abstract][Full Text] [Related]
11. Invasive mucormycosis in a tertiary care hospital in the western region of Saudi Arabia: 11-year retrospective chart review from 2009 to 2019.
Almarhabi H; Al-Asmari E; Munshi A; Farahat F; Al-Amri A; Almaghraby HQ; Alharbi M; Althaqafi A
J Infect Public Health; 2022 Dec; 15(12):1466-1471. PubMed ID: 36403403
[TBL] [Abstract][Full Text] [Related]
12. Clinical factors affecting costs in patients receiving systemic antifungal therapy in intensive care units in Greece: Results from the ESTIMATOR study.
Armaganidis A; Nanas S; Antoniadou E; Mandragos K; Liakou K; Koutsoukou A; Baltopoulos G; Nakos G; Kounougeri A; Ganas K; Prekates A; Kompoti M; Georgopoulos D; Pneumatikos I; Zakynthinos E
Mycoses; 2017 Jul; 60(7):454-461. PubMed ID: 28425571
[TBL] [Abstract][Full Text] [Related]
13. Antifungal treatment in haematological and oncological patients: Need for quality assessment in routine care.
Lachenmayr SJ; Berking S; Horns H; Strobach D; Ostermann H; Berger K
Mycoses; 2018 Jul; 61(7):464-471. PubMed ID: 29575106
[TBL] [Abstract][Full Text] [Related]
14. Mucormycosis in hematologic patients.
Pagano L; Offidani M; Fianchi L; Nosari A; Candoni A; Picardi M; Corvatta L; D'Antonio D; Girmenia C; Martino P; Del Favero A;
Haematologica; 2004 Feb; 89(2):207-14. PubMed ID: 15003897
[TBL] [Abstract][Full Text] [Related]
15. Mucormycosis at a tertiary care centre in Gujarat, India.
Patel AK; Patel KK; Patel K; Gohel S; Chakrabarti A
Mycoses; 2017 Jun; 60(6):407-411. PubMed ID: 28276102
[TBL] [Abstract][Full Text] [Related]
16. Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK.
Bagshaw E; Enoch DA; Blackney M; Posthumus J; Kuessner D
Future Microbiol; 2018 Sep; 13(11):1283-1293. PubMed ID: 29911889
[TBL] [Abstract][Full Text] [Related]
17. Mucormycosis at a tertiary-care center in Mexico. A 35-year retrospective study of 214 cases.
Bonifaz A; Tirado-Sánchez A; Hernández-Medel ML; Araiza J; Kassack JJ; Del Angel-Arenas T; Moisés-Hernández JF; Paredes-Farrera F; Gómez-Apo E; Treviño-Rangel RJ; González GM
Mycoses; 2021 Apr; 64(4):372-380. PubMed ID: 33253454
[TBL] [Abstract][Full Text] [Related]
18. The disease burden of mucormycosis in Japan: results from a systematic literature review and retrospective database study.
Ueno R; Nishimura S; Fujimoto G; Ainiwaer D
Curr Med Res Opin; 2021 Feb; 37(2):253-260. PubMed ID: 33143482
[TBL] [Abstract][Full Text] [Related]
19. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies.
Abidi MZ; Sohail MR; Cummins N; Wilhelm M; Wengenack N; Brumble L; Shah H; Jane Hata D; McCullough A; Wendel A; Vikram HR; Kusne S; Litzow M; Letendre L; Lahr BD; Poeschla E; Walker RC
Mycoses; 2014 Nov; 57(11):687-98. PubMed ID: 25040241
[TBL] [Abstract][Full Text] [Related]
20. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007).
Lanternier F; Dannaoui E; Morizot G; Elie C; Garcia-Hermoso D; Huerre M; Bitar D; Dromer F; Lortholary O;
Clin Infect Dis; 2012 Feb; 54 Suppl 1():S35-43. PubMed ID: 22247443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
